Chapter 14 Atopic Dermatitis (Atopic Eczema)

fitzpatricksdermatology.com

Chapter 14 Atopic Dermatitis (Atopic Eczema)

Chapter 14

Atopic Dermatitis

(Atopic Eczema)

Donald Y.M. Leung, Lawrence F. Eichenfield,

& Mark Boguniewicz

REFERENCES

1. Eichenfield LF et al: Consensus conference on

pediatric atopic dermatitis. J Am Acad Dermatol

49:1088, 2003 [PMID 14639390]

2. Schultz-Larsen F, Hanifin JM: Epidemiology of

atopic dermatitis. Immunol Allergy Clin N Am 22:1,

2002

3. Odhiambo JA et al: Global variations in prevalence

of eczema symptoms in children from

ISAAC Phase Three. J Allergy Clin Immunol

124:1251, 2009 [PMID 20004783]

4. Tay YK et al: The prevalence and descriptive

epidemiology of atopic dermatitis in Singapore

school children. Br J Dermatol 146:101, 2002

[PMID 11841373]

5. Eichenfield LF et al: Atopic dermatitis and asthma:

Parallels in the evolution of treatment. Pediatrics

111:608, 2003 [PMID 12612244]

6. von Mutius E: Gene-environment interactions in

asthma. J Allergy Clin Immunol 123:3, 2009 [PMID

19130922]

7. Strachan DP: Hay fever, hygiene, and household

size. BMJ 299:1259, 1989 [PMID 2513902]

8. Bieber T: Atopic dermatitis. N Engl J Med 358:1483,

2008 [PMID 18385500]

9. Cork MJ et al: Epidermal barrier dysfunction in

atopic dermatitis. J Invest Dermatol 129:1892,

2009 [PMID 19494826]

10. O’Regan GM et al: Filaggrin in atopic dermatitis.

J Allergy Clin Immunol 122:689, 2008 [PMID

18774165]

11. Spergel JM et al: Epicutaneous sensitization with

protein antigen induces localized allergic dermatitis

and hyperresponsiveness to methacholine

after single exposure to aerosolized antigen in

mice. J Clin Invest 101:1614, 1998 [PMID 9541491]

12. Hamid Q, Boguniewicz M, Leung DY: Differential

in situ cytokine gene expression in acute versus

chronic atopic dermatitis. J Clin Invest 94:870,

1994 [PMID 8040343]

13. Werfel T: The role of leukocytes, keratinocytes,

and allergen-specific IgE in the development

of atopic dermatitis. J Invest Dermatol 129:1878,

2009 [PMID 19357709]

14. Sonkoly E et al: IL-31: A new link between T cells

and pruritus in atopic skin inflammation. J Allergy

Clin Immunol 117:411, 2006 [PMID 16461142]

15. Bratton DL et al: Granulocyte macrophage colony-stimulating

factor contributes to enhanced

monocyte survival in chronic atopic dermatitis. J

Clin Invest 95:211, 1995 [PMID 7814618]

16. Toda M et al: Polarized in vivo expression of IL-11

and IL-17 between acute and chronic skin lesions.

J Allergy Clin Immunol 111:875, 2003 [PMID

12704372]

17. Leung DY et al: New insights into atopic dermatitis.

J Clin Invest 113:651, 2004 [PMID 14991059]

18. Novak N et al: Dendritic cells: Bridging innate and

adaptive immunity in atopic dermatitis. J Allergy

Clin Immunol 125:50, 2010 [PMID 20109736]

19. Wollenberg A et al: Plasmacytoid dendritic cells: A

new cutaneous dendritic cell subset with distinct

role in inflammatory skin diseases. J Invest Dermatol

119:1096, 2002 [PMID 12445198]

20. Novak N et al: Characterization of FcepsilonRIbearing

CD123 blood dendritic cell antigen-2

plasmacytoid dendritic cells in atopic dermatitis.

J Allergy Clin Immunol 114:364, 2004 [PMID

15316517]

21. Baud O et al: Treatment of the immune dysregulation,

polyendocrinopathy, enteropathy, X-linked

syndrome (IPEX) by allogeneic bone marrow

transplantation. N Engl J Med 344:1758, 2001

[PMID 11396442]

22. Hoetzenecker W et al: Pimecrolimus leads to an

apoptosis-induced depletion of T cells but not

Langerhans cells in patients with atopic dermatitis.

J Allergy Clin Immunol 115:1276, 2005 [PMID

15940147]

23. Akdis CA, Blaser K, Akdis M: Apoptosis in tissue

inflammation and allergic disease. Curr Opin Immunol

16:717, 2004 [PMID 15511663]


76 Chapter 14: Atopic Dermatitis (Atopic Eczema)

24. Chatila TA: Role of regulatory T cells in human diseases.

J Allergy Clin Immunol 116:949, 2005 [PMID

16275360]

25. Verhagen J et al: Absence of T-regulatory cell

expression and function in atopic dermatitis

skin. J Allergy Clin Immunol 117:176, 2006 [PMID

16387603]

26. Cardona ID: Staphylococcal enterotoxin B inhibits

regulatory T cells by inducing glucocorticoidinduced

TNF receptor-related protein ligand on

monocytes. J Allergy Clin Immunol 117:688, 2006

[PMID 16522472]

27. Di Cesare A, Di Meglio P, Nestle FO: A role for Th17

cells in the immunopathogenesis of atopic dermatitis?

J Invest Dermatol 128:2569, 2008 [PMID

18927538]

28. Burgler S et al: Differentiation and functional

analysis of human T(H)17 cells. J Allergy Clin Immunol

123:588, 2009 [PMID 19178935]

29. Guttman-Yassky E et al: Low expression of the IL-

23/Th17 pathway in atopic dermatitis compared

to psoriasis. J Immunol 181:7420, 2008 [PMID

18981165]

30. Eyerich K et al: IL-17 in atopic eczema: Linking allergen-specific

adaptive and microbial-triggered

innate immune response. J Allergy Clin Immunol

123:59, 2009 [PMID 19056110]

31. Nograles KE et al: IL-22-producing “T22” T cells

account for upregulated IL-22 in atopic dermatitis

despite reduced IL-17-producing TH17 T

cells. J Allergy Clin Immunol 123:1244, 2009 [PMID

19439349]

32. Giustizieri ML et al: Keratinocytes from patients

with atopic dermatitis and psoriasis show a distinct

chemokine production profile in response

to T cell-derived cytokines. J Allergy Clin Immunol

107:871, 2001 [PMID 11344355]

33. Ziegler SF, Artis D: Sensing the outside world:

TSLP regulates barrier immunity. Nat Immunol

11:289, 2010[PMID 20300138]

34. Zhang Z et al: Thymic stromal lymphopoietin

overproduced by keratinocytes in mouse skin

aggravates experimental asthma. Proc Natl Acad

Sci USA 106(5):1536-1541, 2009

35. Demehri S et al: Skin-derived TSLP triggers

progression from epidermal-barrier defects to

asthma. PLoS Biol 7(5):e1000067, 2009 [Epub May

19, 2009]

36. De Benedetto A et al: Atopic dermatitis: A disease

caused by innate immune defects? J Invest Dermatol

129:14, 2009 [PMID 19078985]

37. Barnes KC: An update on the genetics of atopic

dermatitis: Scratching the surface in 2009. J Allergy

Clin Immunol 125:16, 2010 [PMID 20109730]

38. Rodriguez E et al: Meta-analysis of filaggrin polymorphisms

in eczema and asthma: Robust risk

factors in atopic disease. J Allergy Clin Immunol

123:1361, 2009 [PMID 19501237]

39. Klein PA, Clark RA: An evidence-based review of

the efficacy of antihistamines in relieving pruritus

in atopic dermatitis. Arch Dermatol 135:1522,

1999 [PMID 10606058]

40. Yu B et al: Polymorphisms in human histamine

receptor H4 gene are associated with atopic dermatitis.

Br J Dermatol 2010 [Epub ahead of print]

41. Eichenfield LF et al: Safety and efficacy of

pimecrolimus (ASM 981) cream 1% in the treatment

of mild and moderate atopic dermatitis in

children and adolescents. J Am Acad Dermatol

46:495, 2002 [PMID 11907497]

42. Van Der Meer JB et al: The management of moderate

to severe atopic dermatitis in adults with

topical fluticasone propionate. The Netherlands

Adult Atopic Dermatitis Study Group. Br J Dermatol

140:1114, 1999 [PMID 10354080]

43. Bilsborough J et al: IL-31 is associated with cutaneous

lymphocyte antigen-positive skin homing

T cells in patients with atopic dermatitis. J Allergy

Clin Immunol 117:418, 2006 [PMID 16461143]

44. Steinhoff M, Biro T: A TR(I)P to pruritus research:

Role of TRPV3 in inflammation and itch. J Invest

Dermatol 129:531, 2009 [PMID 19209153]

45. Hanifin JM, Rakja G: Diagnostic features of atopic

dermatitis. Acta Derm Venereol 92:44, 1980

46. Williams HC et al: The UK Working Party’s Diagnostic

Criteria for Atopic Dermatitis. I. Derivation

of a minimum set of discriminators for atopic

dermatitis. Br J Dermatol 131:383, 1994 [PMID

7918015]

47. Zhang Q et al: Combined immunodeficiency

associated with DOCK8 mutations. N Engl J Med

361:2046, 2009 [PMID 19776401]

48. Boguniewicz M, Leung DY: Recent insights into

atopic dermatitis and implications for management

of infectious complications. J Allergy Clin

Immunol 125:4, 2010[PMID 20109729]

49. Schlievert PM et al: Secreted virulence factor

comparison between methicillin-resistant and

methicillin-sensitive Staphylococcus aureus, and

its relevance to atopic dermatitis. J Allergy Clin

Immunol 125:39, 2010 [PMID 20109735]

Copyright© McGraw-Hill Companies, Inc. All rights reserved.


Chapter 14: Atopic Dermatitis (Atopic Eczema) 77

50. Müller S et al: Association of Filaggrin loss-offunction-mutations

with atopic dermatitis and

asthma in the Early Treatment of the Atopic Child

(ETAC) population. Pediatr Allergy Immunol 20:358,

2009 [PMID 19538357]

51. Krakowski AC, Eichenfield LF, Dohil MA: Management

of atopic dermatitis in the pediatric population.

Pediatrics 122:812, 2008 [PMID 18829806]

52. Nicol NH, Boguniewicz M: Successful strategies

in atopic dermatitis management. Dermatol Nurs

Suppl.:3, 2008 [PMID 19102292]

53. Akdis CA et al: Diagnosis and treatment of atopic

dermatitis in children and adults: European Academy

of Allergology and Clinical Immunology/

American Academy of Allergy, Asthma and Immunology/PRACTALL

Consensus Report. J Allergy

Clin Immunol 118:152, 2006 [PMID 16815151]

54. Kezic S et al: Loss-of-function mutations in the

filaggrin gene lead to reduced level of natural

moisturizing factor in the stratum corneum. J

Invest Dermatol 128:2117, 2008 [PMID 18305568]

55. Chiang C, Eichenfield LF: Quantitative assessment

of combination bathing and moisturizing

regimens on skin hydration in atopic dermatitis.

Pediatr Dermatol 26:273, 2009 [PMID 19706087]

56. Boguniewicz M et al: MAS063DP is effective

monotherapy for mild to moderate atopic

dermatitis in infants and children: A multicenter,

randomized, vehicle-controlled study. J Pediatr

152:854, 2008 [PMID 18492531]

57. Sugarman JL, Parish LC: Efficacy of a lipid-based

barrier repair formulation in moderate-to-severe

pediatric atopic dermatitis. J Drugs Dermatol

8:1106, 2009 [PMID 20027938]

58. Boguniewicz M et al: A multidisciplinary approach

to evaluation and treatment of atopic

dermatitis. Semin Cutan Med Surg 27:115, 2008

[PMID 18620133]

59. Devillers AC, Oranje AP: Efficacy and safety of

‘wet-wrap’ dressings as an intervention treatment

in children with severe and/or refractory atopic

dermatitis: A critical review of the literature. Br J

Dermatol 154:579, 2006 [PMID 16536797]

60. Jensen JM et al: Different effects of pimecrolimus

and betamethasone on the skin barrier in

patients with atopic dermatitis. J Allergy Clin

Immunol 123:1124, 2009 [PMID 19410693]

61. Friedlander SF, Hebert AA, Allen DB: Safety of

fluticasone propionate cream 0.05% for the treatment

of severe and extensive atopic dermatitis

in children as young as 3 months. J Am Acad

Dermatol 46:387, 2002 [PMID 11862174]

62. Dohil MA, Alvarez-Connelly E, Eichenfield LF:

Fluocinolone acetonide 0.01% in peanut oil:

Safety and efficacy data in the treatment of childhood

atopic dermatitis in infants as young as 3

months of age. Pediatr Dermatol 26:262, 2009

[PMID 19706085]

63. Eichenfield L et al: Evaluation of adrenal suppression

of a lipid enhanced, topical emollient cream

formulation of hydrocortisone butyrate 0.1% in

treating children with atopic dermatitis. Pediatr

Dermatol 24:81, 2007 [PMID 17300659]

64. Eichenfield LF et al: Effect of desonide hydrogel

0.05% on the hypothalamic-pituitary-adrenal

axis in pediatric subjects with moderate to severe

atopic dermatitis. Pediatr Dermatol 24:289, 2007

[PMID 17542883]

65. Eichenfield LF, Miller BH: Two randomized,

double-blind, placebo-controlled studies of fluticasone

propionate lotion 0.05% for the treatment

of atopic dermatitis in subjects from 3 months

of age. J Am Acad Dermatol 54:715, 2006 [PMID

16546598]

66. Berth-Jones J et al: Twice weekly fluticasone

propionate added to emollient maintenance

treatment to reduce risk of relapse in atopic dermatitis:

Randomised, double blind, parallel group

study. BMJ 326:1367, 2003 [PMID 12816824]

67. Wollenberg A, Bieber T: Proactive therapy of

atopic dermatitis–An emerging concept. Allergy

64:276, 2009 [PMID 19076538]

68. Hultsch T, Kapp A, Spergel J: Immunomodulation

and safety of topical calcineurin inhibitors for

the treatment of atopic dermatitis. Dermatology

211:174, 2005 [PMID 16088174]

69. Hanifin JM et al: Efficacy and safety of tacrolimus

ointment treatment for up to 4 years in patients

with atopic dermatitis. J Am Acad Dermatol

53:S186, 2005 [PMID 16021174]

70. Papp KA et al: Long-term control of atopic dermatitis

with pimecrolimus cream 1% in infants

and young children: A two-year study. J Am Acad

Dermatol 52:240, 2005 [PMID 15692468]

71. Queille-Roussel C et al: The new topical ascomycin

derivative SDZ ASM 981 does not induce skin

atrophy when applied to normal skin for 4 weeks:

A randomized, double-blind controlled study. Br J

Dermatol 144:507, 2001 [PMID 11260007]

72. Paul C et al: Safety and tolerability of 1% pimecrolimus

cream among infants: Experience with

1133 patients treated for up to 2 years. Pediatrics

117:e118, 2006 [PMID 16361223]

Copyright© McGraw-Hill Companies, Inc. All rights reserved.


78 Chapter 14: Atopic Dermatitis (Atopic Eczema)

73. Berger TG et al: The use of topical calcineurin inhibitors

in dermatology: Safety concerns. Report

of the American Academy of Dermatology Association

Task Force. J Am Acad Dermatol 54:818,

2006 [PMID 16635663]

74. Arellano FM et al: Risk of lymphoma following

exposure to calcineurin inhibitors and topical

steroids in patients with atopic dermatitis. J Invest

Dermatol 127:808, 2007 [PMID 17096020]

75. Breneman D et al: Intermittent therapy for flare

prevention and long-term disease control in stabilized

atopic dermatitis: A randomized comparison

of 3-times-weekly applications of tacrolimus

ointment versus vehicle. J Am Acad Dermatol

58:990, 2008 [PMID 18359127]

76. Paller AS et al: Three times weekly tacrolimus

ointment reduces relapse in stabilized atopic

dermatitis: A new paradigm for use. Pediatrics

122:e1210, 2008 [PMID 19015204]

77. Zug KA et al: Contact allergy in children referred

for patch testing: North American Contact Dermatitis

Group data, 2001–2004. Arch Dermatol

144:1329, 2008 [PMID 18936397]

78. Leung DY: Infection in atopic dermatitis. Curr

Opin Pediatr 15:399, 2003 [PMID 12891053]

79. Koning S et al: Interventions for impetigo. Cochrane

Database Syst Rev CD003261, 2004 [PMID

15106198]

80. Niebuhr M et al: Antibiotic treatment of cutaneous

infections with Staphylococcus aureus in patients

with atopic dermatitis: Current antimicrobial

resistances and susceptibilities. Exp Dermatol

17:953, 2008 [PMID 18557929]

81. Huang JT et al: Treatment of Staphylococcus aureus

colonization in atopic dermatitis decreases

disease severity. Pediatrics 123:e808, 2009 [PMID

19403473]

82. Langeveld-Wildschut EG et al: Modulation of the

atopy patch test reaction by topical corticosteroids

and tar. J Allergy Clin Immunol 106:737, 2000

[PMID 11031345]

83. Paghdal KV, Schwartz RA: Topical tar: Back to the

future. J Am Acad Dermatol 61:294, 2009 [PMID

19185953]

84. Lyakhovitsky A et al: Low-dose methotrexate

treatment for moderate-to-severe atopic dermatitis

in adults. J Eur Acad Dermatol Venereol 24:43,

2010 [PMID 19552716]

85. Berth-Jones J et al: Azathioprine in severe adult

atopic dermatitis: A double-blind, placebocontrolled,

crossover trial. Br J Dermatol 147:324,

2002 [PMID 12174106]

86. Hon KL et al: Efficacy and tolerability at 3 and 6

months following use of azathioprine for recalcitrant

atopic dermatitis in children and young

adults. J Dermatolog Treat 20:141, 2009 [PMID

18951236]

87. Wolverton SE: Optimizing clinical use of azathioprine

with newer pharmacogenetic data. Arch

Dermatol 145:707, 2009 [PMID 19528429]

88. Hanifin JM et al: Recombinant interferon gamma

therapy for atopic dermatitis. J Am Acad Dermatol

28:189, 1993 [PMID 8432915]

89. Schneider LC et al: Long-term therapy with

recombinant interferon-gamma (rIFN-gamma)

for atopic dermatitis. Ann Allergy Asthma Immunol

80:263, 1998 [PMID 9532976]

90. Stevens SR et al: Long-term effectiveness and

safety of recombinant human interferon gamma

therapy for atopic dermatitis despite unchanged

serum IgE levels. Arch Dermatol 134:799, 1998

[PMID 9681342]

91. Krathen RA, Hsu S: Failure of omalizumab for

treatment of severe adult atopic dermatitis. J Am

Acad Dermatol 53:338, 2005 [PMID 16021135]

92. Lane JE et al: Treatment of recalcitrant atopic

dermatitis with omalizumab. J Am Acad Dermatol

54:68, 2006 [PMID 16384758]

93. Belloni B et al: Low-dose anti-IgE therapy in

patients with atopic eczema with high serum

IgE levels. J Allergy Clin Immunol 120:1223, 2007

[PMID 17936892]

94. Werfel T et al: Usefulness of specific immunotherapy

in patients with atopic dermatitis and allergic

sensitization to house dust mites: A multi-centre,

randomized, dose-response study. Allergy 61:202,

2006 [PMID 16409197]

95. Pajno GB et al: Sublingual immunotherapy in

mite-sensitized children with atopic dermatitis:

A randomized, double-blind, placebo-controlled

study. J Allergy Clin Immunol 120:164, 2007 [PMID

17543376]

96. Richter HI et al: Successful monotherapy of severe

and intractable atopic dermatitis by photopheresis.

J Am Acad Dermatol 38(4):585-588, 1998

97. Kalliomaki M et al: Probiotics in primary prevention

of atopic disease: A randomised placebocontrolled

trial. Lancet 357:1076, 2001 [PMID

11297958]

98. Kalliomaki M et al: Probiotics and prevention of

atopic disease: 4-year follow-up of a randomised

placebo-controlled trial. Lancet 361:1869, 2003

[PMID 12788576]

Copyright© McGraw-Hill Companies, Inc. All rights reserved.


Chapter 14: Atopic Dermatitis (Atopic Eczema) 79

99. Rosenfeldt V et al: Effect of probiotic Lactobacillus

strains in children with atopic dermatitis. J Allergy

Clin Immunol 111:389, 2003 [PMID 12589361]

100. Weston S et al: Effects of probiotics on atopic

dermatitis: A randomised controlled trial. Arch Dis

Child 90:892, 2005 [PMID 15863468]

101. Smits HH et al: Selective probiotic bacteria induce

IL-10-producing regulatory T cells in vitro by

modulating dendritic cell function through dendritic

cell-specific intercellular adhesion molecule

3-grabbing nonintegrin. J Allergy Clin Immunol

115:1260, 2005 [PMID 15940144]

102. Michail SK et al: Efficacy of probiotics in the treatment

of pediatric atopic dermatitis: A meta-analysis

of randomized controlled trials. Ann Allergy

Asthma Immunol 101:508, 2008 [PMID 19055205]

103. Lee J, Seto D, Bielory L: Meta-analysis of clinical

trials of probiotics for prevention and treatment

of pediatric atopic dermatitis. J Allergy Clin Immunol

121:116, 2008 [PMID 18206506]

104. Kopp MV et al: Randomized, double-blind,

placebo-controlled trial of probiotics for primary

prevention: No clinical effects of Lactobacillus

GG supplementation. Pediatrics 121:e850, 2008

[PMID 18332075]

105. Boyle RJ et al: Probiotics for treating eczema. Cochrane

Database Syst Rev CD006135, 2008 [PMID

18843705]

106. Sidbury R et al: Randomized controlled trial of

vitamin D supplementation for winter-related

atopic dermatitis in Boston: A pilot study. Br J

Dermatol 159:245, 2008 [PMID 18489598]

107. Hata TR et al: Administration of oral vitamin D induces

cathelicidin production in atopic individuals.

J Allergy Clin Immunol 122:829, 2008 [PMID

19014773]

108. Miller J, Gallo RL: Vitamin D and innate immunity.

Dermatol Ther 23:13, 2010 [PMID 20136905]

109. Staab D et al: Age related, structured educational

programmes for the management of atopic

dermatitis in children and adolescents: Multicentre,

randomised controlled trial. BMJ 332:933,

2006[PMID: 16627509]

Copyright© McGraw-Hill Companies, Inc. All rights reserved.

More magazines by this user
Similar magazines